Admin Posted June 2, 2019 Share Posted June 2, 2019 For metastatic castrate-resistant prostate cancer, Enzalutamide (Xtandi) works. For metastatic castrate-resistant prostate cancer, Abiraterone (Zytiga) works, but in a different way. So, perhaps using both at once might be better. Sorry. No. Dr Michael Morris reported to the ASCO (American Society of Clinical Oncology) 2019 meeting on the results of the Alliance A031201 clinical trial. On behalf of the team of doctors that did the trial, Dr Morris said: Adding abiraterone to enzalutamide does not improve OS relative to enzalutamide alone Enzalutamide/abiraterone has a modest improvement in rPFS On-treatment rPFS and OS were similar to previous studies Enzalutamide/abiraterone caused more adverse events than enzalutamide alone The current standard of care is unchanged by this study The following article is not on this site. If you click on the link below, you will be taken to a site where we do not control the content. So, please be careful about what you read there, and ask your doctor about anything you read. You may need to subscribe to the site to view the article. If it is temporarily or permanently unavailable, you may receive an error message. https://www.urotoday.com/conference-highlights/asco-2019-annual-meeting/asco-2019-prostate-cancer/112921-asco-2019-enzalutamide-versus-enzalutamide-abiraterone-and-prednisone-for-metastatic-castration-resistant-prostate-cancer-alliance-a031201.html?utm_source=newsletter_6632&utm_medium=email&utm_campaign=prostate-practice-changing-date-from-asco-2019 Link to comment Share on other sites More sharing options...
This topic is now archived and is closed to further replies.